CD117 (c-kit) expression in human hepatocellular carcinoma.

Authors :: Becker G
Schmitt-Graeff A
Ertelt V
Blum HE
Allgaier HP
Source :: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2007 Apr; Vol. 19 (3), pp. 204-8. Date of Electronic Publication: 2007 Jan 12.
Publication Year :: 2007
Abstract: Aims: Although various methods of treatment have been tried, treatment options for advanced hepatocellular carcinoma (HCC) remain limited. Expression of the platelet-derived growth factor has been shown in HCC, which may derive from hepatic stem cells that express the c-kit proto-oncogene. Because of the promising results of imatinib and the key role played by c-kit in gastrointestinal stromal tumours and other solid tumours, the aim of this study was to determine the prevalence of c-kit (CD117) overexpression in patients with HCC.<br />Materials and Methods: A retrospective study of 258 archival specimens of subjects with histologically confirmed HCC was carried out. Expression of the c-kit proto-oncogene was evaluated by immunohistochemistry using rabbit anti-CD117 antibody A4502.<br />Results: The overall percentage of positive immunohistochemical staining of HCCs was 2.3% (6/258).<br />Conclusions: Our results suggest that CD117 is not significantly overexpressed in HCC and there seems to be no role for the use of imatinib.

Language :: English
ISSN :: 0936-6555
Volume :: 19
Issue :: 3
Database :: MEDLINE
Journal :: Clinical oncology (Royal College of Radiologists (Great Britain))
Publication Type :: Academic Journal
Accession number :: 17359908
Full Text :: https://doi.org/10.1016/j.clon.2006.12.009